Safety of besifloxacin ophthalmic suspension 0.6% as a prophylactic antibiotic following routine cataract surgery: results of a prospective, parallel-group, investigator-masked study
Ranjan Malhotra,1 Joseph Gira,2 Gregg J Berdy,1 Robert Brusatti11Ophthalmology Associates, 2Ophthalmology Consultants, St Louis, MO, USABackground: The purpose of this study was to evaluate the safety and tolerability of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic s...
Guardado en:
Autores principales: | Malhotra R, Gira J, Berdy GJ, Brusatti R |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e4f699980d804b389677dc6cd7d6bc6f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections
por: Silverstein BE, et al.
Publicado: (2012) -
Antibacterial efficacy of prophylactic besifloxacin 0.6% and moxifloxacin 0.5% in patients undergoing cataract surgery
por: Bucci FA Jr, et al.
Publicado: (2015) -
Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: microbiological eradication outcomes
por: Morris TW, et al.
Publicado: (2011) -
Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients
por: Nielsen SA, et al.
Publicado: (2013) -
Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients
por: Nielsen SA, et al.
Publicado: (2013)